menu
    • menu
    [{"orgOrder":0,"company":"ZYMEDI","sponsor":"National Heart, Lung, and Blood Institute","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Large molecule","year":"2023","type":"Collaboration","leadProduct":"ZMA001","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"ZYMEDI","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"ZYMEDI \/ National Heart, Lung, and Blood Institute","highestDevelopmentStatusID":"4","companyTruncated":"ZYMEDI \/ National Heart, Lung, and Blood Institute"},{"orgOrder":0,"company":"ZYMEDI","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"BC-NKA-20008","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"ZYMEDI","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"ZYMEDI \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"ZYMEDI \/ Not Applicable"},{"orgOrder":0,"company":"ZYMEDI","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"BC-NKA-20008","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"ZYMEDI","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"ZYMEDI \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"ZYMEDI \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals by ZYMEDI

    Menu

    ZYMEDI

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            ZYMEDI

                            South Korea arrow
                            Compamed
                            Not Confirmed

                            ZYMEDI

                            South Korea arrow
                            Compamed
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : BC-NKA-20008

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            FDA Grants Orphan Drug Status to Zymedi's ZMA001 for Pulmonary Arterial Hypertension

                            Details : ZMA001 (BC-NKA-20008) is a first-in-class therapeutic antibody targeting KARS1 that is specific to monocytes & macrophages. It is being evaluated for the treatment of pulmonary arterial hypertension.

                            Brand Name : ZMA001

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            July 30, 2024

                            Lead Product(s) : BC-NKA-20008

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            ZYMEDI

                            South Korea arrow
                            Compamed
                            Not Confirmed

                            ZYMEDI

                            South Korea arrow
                            Compamed
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : BC-NKA-20008

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            First Patient Dosed in ZMA001 Trial for Pulmonary Arterial Hypertension

                            Details : ZMA001 is a first-in-class therapeutic antibody targeting KARS1, specific to monocytes and macrophages, under phase 1 trials for treating pulmonary arterial hypertension.

                            Brand Name : ZMA001

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            February 07, 2024

                            Lead Product(s) : BC-NKA-20008

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            ZYMEDI

                            South Korea arrow
                            Compamed
                            Not Confirmed

                            ZYMEDI

                            South Korea arrow
                            Compamed
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ZMA001

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Preclinical

                            Sponsor : National Heart, Lung, and Blood Institute

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Zymedi Announced their Collaboration with the National Heart, Lung, and Blood Institute through a CTA CRADA to...

                            Details : The agreement aims to develop ZMA001, a novel monoclonal antibody targeting pathways thought to play a key role in PAH pathogenesis, for the treatment of pulmonary arterial hypertension (PAH).

                            Brand Name : ZMA001

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            July 02, 2023

                            Lead Product(s) : ZMA001

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Preclinical

                            Sponsor : National Heart, Lung, and Blood Institute

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth